nodes	percent_of_prediction	percent_of_DWPC	metapath
Midodrine—ADRA1B—vas deferens—prostate cancer	0.099	0.615	CbGeAlD
Midodrine—CYP2D6—Bicalutamide—prostate cancer	0.084	0.505	CbGbCtD
Midodrine—CYP2D6—Abiraterone—prostate cancer	0.0696	0.418	CbGbCtD
Midodrine—CYP2D6—Doxorubicin—prostate cancer	0.0129	0.0773	CbGbCtD
Midodrine—ADRA1D—prostate gland—prostate cancer	0.00864	0.0537	CbGeAlD
Midodrine—CYP2D6—urine—prostate cancer	0.00815	0.0506	CbGeAlD
Midodrine—Melatonin—CALR—prostate cancer	0.00698	0.511	CrCbGaD
Midodrine—ADRA1D—epithelium—prostate cancer	0.00635	0.0395	CbGeAlD
Midodrine—SLC15A1—epithelium—prostate cancer	0.00612	0.038	CbGeAlD
Midodrine—ADRA1B—renal system—prostate cancer	0.00602	0.0374	CbGeAlD
Midodrine—ADRA1D—urethra—prostate cancer	0.00579	0.0359	CbGeAlD
Midodrine—SLC15A1—renal system—prostate cancer	0.00568	0.0353	CbGeAlD
Midodrine—ADRA1A—prostate gland—prostate cancer	0.00497	0.0308	CbGeAlD
Midodrine—ADRA1A—epithelium—prostate cancer	0.00365	0.0227	CbGeAlD
Midodrine—ADRA1A—renal system—prostate cancer	0.00338	0.021	CbGeAlD
Midodrine—CYP2D6—renal system—prostate cancer	0.00199	0.0124	CbGeAlD
Midodrine—Melatonin—CYP1B1—prostate cancer	0.00152	0.111	CrCbGaD
Midodrine—Melatonin—MPO—prostate cancer	0.00137	0.1	CrCbGaD
Midodrine—CYP2D6—testis—prostate cancer	0.00129	0.008	CbGeAlD
Midodrine—Melatonin—CYP19A1—prostate cancer	0.00112	0.0818	CrCbGaD
Midodrine—Melatonin—ESR1—prostate cancer	0.00103	0.0752	CrCbGaD
Midodrine—Melatonin—CYP2C19—prostate cancer	0.000825	0.0604	CrCbGaD
Midodrine—Melatonin—CYP1A1—prostate cancer	0.000822	0.0602	CrCbGaD
Midodrine—Skin disorder—Mitoxantrone—prostate cancer	0.000454	0.000905	CcSEcCtD
Midodrine—Insomnia—Estradiol—prostate cancer	0.000454	0.000904	CcSEcCtD
Midodrine—Paraesthesia—Estradiol—prostate cancer	0.000451	0.000898	CcSEcCtD
Midodrine—Asthenia—Conjugated Estrogens—prostate cancer	0.00045	0.000896	CcSEcCtD
Midodrine—Urinary tract disorder—Docetaxel—prostate cancer	0.000449	0.000895	CcSEcCtD
Midodrine—Bradycardia—Capecitabine—prostate cancer	0.000449	0.000893	CcSEcCtD
Midodrine—Pruritus—Goserelin—prostate cancer	0.000448	0.000892	CcSEcCtD
Midodrine—Dyspnoea—Estradiol—prostate cancer	0.000447	0.000891	CcSEcCtD
Midodrine—Somnolence—Estradiol—prostate cancer	0.000446	0.000889	CcSEcCtD
Midodrine—Urethral disorder—Docetaxel—prostate cancer	0.000446	0.000888	CcSEcCtD
Midodrine—Pruritus—Conjugated Estrogens—prostate cancer	0.000444	0.000884	CcSEcCtD
Midodrine—Dyspepsia—Estradiol—prostate cancer	0.000442	0.00088	CcSEcCtD
Midodrine—Urinary tract disorder—Capecitabine—prostate cancer	0.000435	0.000866	CcSEcCtD
Midodrine—Gastrointestinal disorder—Estradiol—prostate cancer	0.000433	0.000863	CcSEcCtD
Midodrine—Urethral disorder—Capecitabine—prostate cancer	0.000432	0.00086	CcSEcCtD
Midodrine—Erythema multiforme—Docetaxel—prostate cancer	0.00043	0.000857	CcSEcCtD
Midodrine—Pain—Estradiol—prostate cancer	0.000429	0.000855	CcSEcCtD
Midodrine—Flushing—Docetaxel—prostate cancer	0.000422	0.000841	CcSEcCtD
Midodrine—Cardiac disorder—Docetaxel—prostate cancer	0.000422	0.000841	CcSEcCtD
Midodrine—Paraesthesia—Mitoxantrone—prostate cancer	0.00042	0.000836	CcSEcCtD
Midodrine—Dizziness—Goserelin—prostate cancer	0.000419	0.000834	CcSEcCtD
Midodrine—Dyspnoea—Mitoxantrone—prostate cancer	0.000417	0.00083	CcSEcCtD
Midodrine—Erythema multiforme—Capecitabine—prostate cancer	0.000417	0.00083	CcSEcCtD
Midodrine—Somnolence—Mitoxantrone—prostate cancer	0.000416	0.000828	CcSEcCtD
Midodrine—Dizziness—Conjugated Estrogens—prostate cancer	0.000415	0.000826	CcSEcCtD
Midodrine—Feeling abnormal—Estradiol—prostate cancer	0.000414	0.000824	CcSEcCtD
Midodrine—Angiopathy—Docetaxel—prostate cancer	0.000413	0.000822	CcSEcCtD
Midodrine—Dyspepsia—Mitoxantrone—prostate cancer	0.000412	0.00082	CcSEcCtD
Midodrine—Hypertension—Etoposide—prostate cancer	0.000412	0.00082	CcSEcCtD
Midodrine—Gastrointestinal pain—Estradiol—prostate cancer	0.00041	0.000817	CcSEcCtD
Midodrine—Cardiac disorder—Capecitabine—prostate cancer	0.000409	0.000814	CcSEcCtD
Midodrine—Flushing—Capecitabine—prostate cancer	0.000409	0.000814	CcSEcCtD
Midodrine—Chills—Docetaxel—prostate cancer	0.000408	0.000813	CcSEcCtD
Midodrine—Dry skin—Epirubicin—prostate cancer	0.000407	0.00081	CcSEcCtD
Midodrine—Unspecified disorder of skin and subcutaneous tissue—Etoposide—prostate cancer	0.000403	0.000803	CcSEcCtD
Midodrine—Pain—Mitoxantrone—prostate cancer	0.0004	0.000796	CcSEcCtD
Midodrine—Angiopathy—Capecitabine—prostate cancer	0.0004	0.000796	CcSEcCtD
Midodrine—Bradycardia—Prednisone—prostate cancer	0.0004	0.000796	CcSEcCtD
Midodrine—Rash—Goserelin—prostate cancer	0.000399	0.000795	CcSEcCtD
Midodrine—Dermatitis—Goserelin—prostate cancer	0.000399	0.000794	CcSEcCtD
Midodrine—Mental disorder—Docetaxel—prostate cancer	0.000399	0.000794	CcSEcCtD
Midodrine—Abdominal pain—Estradiol—prostate cancer	0.000397	0.00079	CcSEcCtD
Midodrine—Headache—Goserelin—prostate cancer	0.000397	0.00079	CcSEcCtD
Midodrine—Rash—Conjugated Estrogens—prostate cancer	0.000395	0.000787	CcSEcCtD
Midodrine—Chills—Capecitabine—prostate cancer	0.000395	0.000787	CcSEcCtD
Midodrine—Dermatitis—Conjugated Estrogens—prostate cancer	0.000395	0.000787	CcSEcCtD
Midodrine—Headache—Conjugated Estrogens—prostate cancer	0.000393	0.000782	CcSEcCtD
Midodrine—Confusional state—Etoposide—prostate cancer	0.000392	0.000781	CcSEcCtD
Midodrine—Mental disorder—Capecitabine—prostate cancer	0.000386	0.000769	CcSEcCtD
Midodrine—Feeling abnormal—Mitoxantrone—prostate cancer	0.000385	0.000767	CcSEcCtD
Midodrine—Back pain—Docetaxel—prostate cancer	0.000383	0.000763	CcSEcCtD
Midodrine—Gastrointestinal pain—Mitoxantrone—prostate cancer	0.000382	0.000762	CcSEcCtD
Midodrine—Muscle spasms—Docetaxel—prostate cancer	0.000381	0.000758	CcSEcCtD
Midodrine—Tachycardia—Etoposide—prostate cancer	0.00038	0.000756	CcSEcCtD
Midodrine—Flatulence—Capecitabine—prostate cancer	0.000378	0.000753	CcSEcCtD
Midodrine—Skin disorder—Etoposide—prostate cancer	0.000378	0.000752	CcSEcCtD
Midodrine—Dry skin—Doxorubicin—prostate cancer	0.000376	0.000749	CcSEcCtD
Midodrine—Nausea—Goserelin—prostate cancer	0.000376	0.000749	CcSEcCtD
Midodrine—Nausea—Conjugated Estrogens—prostate cancer	0.000373	0.000742	CcSEcCtD
Midodrine—Back pain—Capecitabine—prostate cancer	0.000371	0.000739	CcSEcCtD
Midodrine—Abdominal pain—Mitoxantrone—prostate cancer	0.00037	0.000736	CcSEcCtD
Midodrine—Muscle spasms—Capecitabine—prostate cancer	0.000369	0.000734	CcSEcCtD
Midodrine—Flushing—Prednisone—prostate cancer	0.000364	0.000725	CcSEcCtD
Midodrine—Asthenia—Estradiol—prostate cancer	0.00036	0.000717	CcSEcCtD
Midodrine—Dysuria—Epirubicin—prostate cancer	0.000359	0.000714	CcSEcCtD
Midodrine—Angiopathy—Prednisone—prostate cancer	0.000356	0.000709	CcSEcCtD
Midodrine—Pruritus—Estradiol—prostate cancer	0.000355	0.000707	CcSEcCtD
Midodrine—Pollakiuria—Epirubicin—prostate cancer	0.000354	0.000705	CcSEcCtD
Midodrine—Paraesthesia—Etoposide—prostate cancer	0.000349	0.000696	CcSEcCtD
Midodrine—Dyspnoea—Etoposide—prostate cancer	0.000347	0.000691	CcSEcCtD
Midodrine—Somnolence—Etoposide—prostate cancer	0.000346	0.000689	CcSEcCtD
Midodrine—Mental disorder—Prednisone—prostate cancer	0.000344	0.000685	CcSEcCtD
Midodrine—Hypertension—Docetaxel—prostate cancer	0.000342	0.000681	CcSEcCtD
Midodrine—Stevens-Johnson syndrome—Epirubicin—prostate cancer	0.000339	0.000675	CcSEcCtD
Midodrine—Gastrointestinal disorder—Etoposide—prostate cancer	0.000336	0.000669	CcSEcCtD
Midodrine—Asthenia—Mitoxantrone—prostate cancer	0.000336	0.000668	CcSEcCtD
Midodrine—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—prostate cancer	0.000335	0.000667	CcSEcCtD
Midodrine—Stomatitis—Epirubicin—prostate cancer	0.000333	0.000664	CcSEcCtD
Midodrine—Pain—Etoposide—prostate cancer	0.000333	0.000662	CcSEcCtD
Midodrine—Dizziness—Estradiol—prostate cancer	0.000332	0.000661	CcSEcCtD
Midodrine—Dysuria—Doxorubicin—prostate cancer	0.000332	0.000661	CcSEcCtD
Midodrine—Hypertension—Capecitabine—prostate cancer	0.000331	0.000659	CcSEcCtD
Midodrine—Dry mouth—Docetaxel—prostate cancer	0.00033	0.000657	CcSEcCtD
Midodrine—Pollakiuria—Doxorubicin—prostate cancer	0.000328	0.000653	CcSEcCtD
Midodrine—Confusional state—Docetaxel—prostate cancer	0.000326	0.000649	CcSEcCtD
Midodrine—Anxiety—Capecitabine—prostate cancer	0.000325	0.000648	CcSEcCtD
Midodrine—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—prostate cancer	0.000324	0.000646	CcSEcCtD
Midodrine—Hepatobiliary disease—Epirubicin—prostate cancer	0.000323	0.000644	CcSEcCtD
Midodrine—Feeling abnormal—Etoposide—prostate cancer	0.000321	0.000638	CcSEcCtD
Midodrine—Dry mouth—Capecitabine—prostate cancer	0.000319	0.000636	CcSEcCtD
Midodrine—Gastrointestinal pain—Etoposide—prostate cancer	0.000318	0.000633	CcSEcCtD
Midodrine—Nervous system disorder—Docetaxel—prostate cancer	0.000317	0.000631	CcSEcCtD
Midodrine—Rash—Estradiol—prostate cancer	0.000316	0.00063	CcSEcCtD
Midodrine—Dermatitis—Estradiol—prostate cancer	0.000316	0.00063	CcSEcCtD
Midodrine—Confusional state—Capecitabine—prostate cancer	0.000316	0.000629	CcSEcCtD
Midodrine—Tachycardia—Docetaxel—prostate cancer	0.000316	0.000628	CcSEcCtD
Midodrine—Headache—Estradiol—prostate cancer	0.000314	0.000626	CcSEcCtD
Midodrine—Skin disorder—Docetaxel—prostate cancer	0.000314	0.000625	CcSEcCtD
Midodrine—Agitation—Prednisone—prostate cancer	0.000314	0.000625	CcSEcCtD
Midodrine—Stevens-Johnson syndrome—Doxorubicin—prostate cancer	0.000314	0.000625	CcSEcCtD
Midodrine—Bradycardia—Epirubicin—prostate cancer	0.000312	0.000622	CcSEcCtD
Midodrine—Stomatitis—Doxorubicin—prostate cancer	0.000308	0.000614	CcSEcCtD
Midodrine—Abdominal pain—Etoposide—prostate cancer	0.000308	0.000612	CcSEcCtD
Midodrine—Nervous system disorder—Capecitabine—prostate cancer	0.000307	0.000611	CcSEcCtD
Midodrine—Tachycardia—Capecitabine—prostate cancer	0.000305	0.000608	CcSEcCtD
Midodrine—Skin disorder—Capecitabine—prostate cancer	0.000304	0.000605	CcSEcCtD
Midodrine—Urinary tract disorder—Epirubicin—prostate cancer	0.000303	0.000604	CcSEcCtD
Midodrine—Urethral disorder—Epirubicin—prostate cancer	0.000301	0.000599	CcSEcCtD
Midodrine—Hepatobiliary disease—Doxorubicin—prostate cancer	0.000299	0.000596	CcSEcCtD
Midodrine—Nausea—Estradiol—prostate cancer	0.000298	0.000594	CcSEcCtD
Midodrine—Hypertension—Prednisone—prostate cancer	0.000295	0.000587	CcSEcCtD
Midodrine—Rash—Mitoxantrone—prostate cancer	0.000295	0.000587	CcSEcCtD
Midodrine—Dermatitis—Mitoxantrone—prostate cancer	0.000295	0.000587	CcSEcCtD
Midodrine—Headache—Mitoxantrone—prostate cancer	0.000293	0.000583	CcSEcCtD
Midodrine—Insomnia—Docetaxel—prostate cancer	0.000292	0.000582	CcSEcCtD
Midodrine—Paraesthesia—Docetaxel—prostate cancer	0.00029	0.000578	CcSEcCtD
Midodrine—Erythema multiforme—Epirubicin—prostate cancer	0.00029	0.000578	CcSEcCtD
Midodrine—Anxiety—Prednisone—prostate cancer	0.00029	0.000577	CcSEcCtD
Midodrine—Bradycardia—Doxorubicin—prostate cancer	0.000289	0.000576	CcSEcCtD
Midodrine—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	0.000289	0.000575	CcSEcCtD
Midodrine—Dyspnoea—Docetaxel—prostate cancer	0.000288	0.000574	CcSEcCtD
Midodrine—Somnolence—Docetaxel—prostate cancer	0.000287	0.000572	CcSEcCtD
Midodrine—Flushing—Epirubicin—prostate cancer	0.000285	0.000567	CcSEcCtD
Midodrine—Cardiac disorder—Epirubicin—prostate cancer	0.000285	0.000567	CcSEcCtD
Midodrine—Dyspepsia—Docetaxel—prostate cancer	0.000285	0.000567	CcSEcCtD
Midodrine—Insomnia—Capecitabine—prostate cancer	0.000283	0.000564	CcSEcCtD
Midodrine—Paraesthesia—Capecitabine—prostate cancer	0.000281	0.00056	CcSEcCtD
Midodrine—Urinary tract disorder—Doxorubicin—prostate cancer	0.00028	0.000559	CcSEcCtD
Midodrine—Gastrointestinal disorder—Docetaxel—prostate cancer	0.000279	0.000556	CcSEcCtD
Midodrine—Asthenia—Etoposide—prostate cancer	0.000279	0.000556	CcSEcCtD
Midodrine—Dyspnoea—Capecitabine—prostate cancer	0.000279	0.000556	CcSEcCtD
Midodrine—Angiopathy—Epirubicin—prostate cancer	0.000278	0.000555	CcSEcCtD
Midodrine—Urethral disorder—Doxorubicin—prostate cancer	0.000278	0.000554	CcSEcCtD
Midodrine—Nausea—Mitoxantrone—prostate cancer	0.000278	0.000553	CcSEcCtD
Midodrine—Pain—Docetaxel—prostate cancer	0.000276	0.000551	CcSEcCtD
Midodrine—Dyspepsia—Capecitabine—prostate cancer	0.000276	0.000549	CcSEcCtD
Midodrine—Chills—Epirubicin—prostate cancer	0.000275	0.000548	CcSEcCtD
Midodrine—Pruritus—Etoposide—prostate cancer	0.000275	0.000548	CcSEcCtD
Midodrine—Nervous system disorder—Prednisone—prostate cancer	0.000273	0.000544	CcSEcCtD
Midodrine—Tachycardia—Prednisone—prostate cancer	0.000272	0.000542	CcSEcCtD
Midodrine—Skin disorder—Prednisone—prostate cancer	0.000271	0.000539	CcSEcCtD
Midodrine—Gastrointestinal disorder—Capecitabine—prostate cancer	0.00027	0.000538	CcSEcCtD
Midodrine—Mental disorder—Epirubicin—prostate cancer	0.000269	0.000535	CcSEcCtD
Midodrine—Erythema multiforme—Doxorubicin—prostate cancer	0.000269	0.000535	CcSEcCtD
Midodrine—Pain—Capecitabine—prostate cancer	0.000268	0.000533	CcSEcCtD
Midodrine—Feeling abnormal—Docetaxel—prostate cancer	0.000266	0.000531	CcSEcCtD
Midodrine—Gastrointestinal pain—Docetaxel—prostate cancer	0.000264	0.000526	CcSEcCtD
Midodrine—Flushing—Doxorubicin—prostate cancer	0.000264	0.000525	CcSEcCtD
Midodrine—Cardiac disorder—Doxorubicin—prostate cancer	0.000264	0.000525	CcSEcCtD
Midodrine—Flatulence—Epirubicin—prostate cancer	0.000263	0.000524	CcSEcCtD
Midodrine—Tension—Epirubicin—prostate cancer	0.000262	0.000522	CcSEcCtD
Midodrine—Nervousness—Epirubicin—prostate cancer	0.00026	0.000517	CcSEcCtD
Midodrine—Back pain—Epirubicin—prostate cancer	0.000258	0.000515	CcSEcCtD
Midodrine—Feeling abnormal—Capecitabine—prostate cancer	0.000258	0.000514	CcSEcCtD
Midodrine—Angiopathy—Doxorubicin—prostate cancer	0.000258	0.000513	CcSEcCtD
Midodrine—Dizziness—Etoposide—prostate cancer	0.000257	0.000512	CcSEcCtD
Midodrine—Muscle spasms—Epirubicin—prostate cancer	0.000257	0.000512	CcSEcCtD
Midodrine—Gastrointestinal pain—Capecitabine—prostate cancer	0.000256	0.00051	CcSEcCtD
Midodrine—Abdominal pain—Docetaxel—prostate cancer	0.000256	0.000509	CcSEcCtD
Midodrine—Chills—Doxorubicin—prostate cancer	0.000255	0.000507	CcSEcCtD
Midodrine—Insomnia—Prednisone—prostate cancer	0.000252	0.000502	CcSEcCtD
Midodrine—Paraesthesia—Prednisone—prostate cancer	0.00025	0.000499	CcSEcCtD
Midodrine—Mental disorder—Doxorubicin—prostate cancer	0.000249	0.000495	CcSEcCtD
Midodrine—Abdominal pain—Capecitabine—prostate cancer	0.000247	0.000493	CcSEcCtD
Midodrine—Agitation—Epirubicin—prostate cancer	0.000246	0.000489	CcSEcCtD
Midodrine—Dyspepsia—Prednisone—prostate cancer	0.000245	0.000489	CcSEcCtD
Midodrine—Rash—Etoposide—prostate cancer	0.000245	0.000488	CcSEcCtD
Midodrine—Dermatitis—Etoposide—prostate cancer	0.000245	0.000488	CcSEcCtD
Midodrine—Headache—Etoposide—prostate cancer	0.000244	0.000485	CcSEcCtD
Midodrine—Flatulence—Doxorubicin—prostate cancer	0.000244	0.000485	CcSEcCtD
Midodrine—Tension—Doxorubicin—prostate cancer	0.000243	0.000483	CcSEcCtD
Midodrine—Nervousness—Doxorubicin—prostate cancer	0.00024	0.000478	CcSEcCtD
Midodrine—Back pain—Doxorubicin—prostate cancer	0.000239	0.000476	CcSEcCtD
Midodrine—Muscle spasms—Doxorubicin—prostate cancer	0.000238	0.000473	CcSEcCtD
Midodrine—Asthenia—Docetaxel—prostate cancer	0.000232	0.000462	CcSEcCtD
Midodrine—Nausea—Etoposide—prostate cancer	0.000231	0.00046	CcSEcCtD
Midodrine—Hypertension—Epirubicin—prostate cancer	0.000231	0.000459	CcSEcCtD
Midodrine—Feeling abnormal—Prednisone—prostate cancer	0.00023	0.000458	CcSEcCtD
Midodrine—Pruritus—Docetaxel—prostate cancer	0.000229	0.000455	CcSEcCtD
Midodrine—Gastrointestinal pain—Prednisone—prostate cancer	0.000228	0.000454	CcSEcCtD
Midodrine—Agitation—Doxorubicin—prostate cancer	0.000227	0.000452	CcSEcCtD
Midodrine—Anxiety—Epirubicin—prostate cancer	0.000227	0.000451	CcSEcCtD
Midodrine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	0.000226	0.00045	CcSEcCtD
Midodrine—Asthenia—Capecitabine—prostate cancer	0.000225	0.000447	CcSEcCtD
Midodrine—Dry mouth—Epirubicin—prostate cancer	0.000222	0.000443	CcSEcCtD
Midodrine—Pruritus—Capecitabine—prostate cancer	0.000221	0.000441	CcSEcCtD
Midodrine—Abdominal pain—Prednisone—prostate cancer	0.00022	0.000439	CcSEcCtD
Midodrine—Confusional state—Epirubicin—prostate cancer	0.00022	0.000438	CcSEcCtD
Midodrine—Nervous system disorder—Epirubicin—prostate cancer	0.000214	0.000426	CcSEcCtD
Midodrine—Dizziness—Docetaxel—prostate cancer	0.000214	0.000426	CcSEcCtD
Midodrine—Hypertension—Doxorubicin—prostate cancer	0.000213	0.000425	CcSEcCtD
Midodrine—Tachycardia—Epirubicin—prostate cancer	0.000213	0.000424	CcSEcCtD
Midodrine—Skin disorder—Epirubicin—prostate cancer	0.000212	0.000422	CcSEcCtD
Midodrine—Anxiety—Doxorubicin—prostate cancer	0.00021	0.000418	CcSEcCtD
Midodrine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	0.000209	0.000416	CcSEcCtD
Midodrine—Dizziness—Capecitabine—prostate cancer	0.000207	0.000412	CcSEcCtD
Midodrine—Dry mouth—Doxorubicin—prostate cancer	0.000206	0.00041	CcSEcCtD
Midodrine—Rash—Docetaxel—prostate cancer	0.000204	0.000406	CcSEcCtD
Midodrine—Dermatitis—Docetaxel—prostate cancer	0.000204	0.000406	CcSEcCtD
Midodrine—Confusional state—Doxorubicin—prostate cancer	0.000203	0.000405	CcSEcCtD
Midodrine—Headache—Docetaxel—prostate cancer	0.000203	0.000403	CcSEcCtD
Midodrine—Asthenia—Prednisone—prostate cancer	0.0002	0.000398	CcSEcCtD
Midodrine—Nervous system disorder—Doxorubicin—prostate cancer	0.000198	0.000394	CcSEcCtD
Midodrine—Rash—Capecitabine—prostate cancer	0.000197	0.000393	CcSEcCtD
Midodrine—Pruritus—Prednisone—prostate cancer	0.000197	0.000393	CcSEcCtD
Midodrine—Insomnia—Epirubicin—prostate cancer	0.000197	0.000393	CcSEcCtD
Midodrine—Dermatitis—Capecitabine—prostate cancer	0.000197	0.000393	CcSEcCtD
Midodrine—Tachycardia—Doxorubicin—prostate cancer	0.000197	0.000392	CcSEcCtD
Midodrine—Headache—Capecitabine—prostate cancer	0.000196	0.00039	CcSEcCtD
Midodrine—Skin disorder—Doxorubicin—prostate cancer	0.000196	0.00039	CcSEcCtD
Midodrine—Paraesthesia—Epirubicin—prostate cancer	0.000196	0.00039	CcSEcCtD
Midodrine—Dyspnoea—Epirubicin—prostate cancer	0.000194	0.000387	CcSEcCtD
Midodrine—Somnolence—Epirubicin—prostate cancer	0.000194	0.000386	CcSEcCtD
Midodrine—Nausea—Docetaxel—prostate cancer	0.000192	0.000382	CcSEcCtD
Midodrine—Dyspepsia—Epirubicin—prostate cancer	0.000192	0.000382	CcSEcCtD
Midodrine—Gastrointestinal disorder—Epirubicin—prostate cancer	0.000188	0.000375	CcSEcCtD
Midodrine—Pain—Epirubicin—prostate cancer	0.000186	0.000371	CcSEcCtD
Midodrine—Nausea—Capecitabine—prostate cancer	0.000186	0.00037	CcSEcCtD
Midodrine—Dizziness—Prednisone—prostate cancer	0.000184	0.000367	CcSEcCtD
Midodrine—Insomnia—Doxorubicin—prostate cancer	0.000182	0.000363	CcSEcCtD
Midodrine—Paraesthesia—Doxorubicin—prostate cancer	0.000181	0.000361	CcSEcCtD
Midodrine—Dyspnoea—Doxorubicin—prostate cancer	0.00018	0.000358	CcSEcCtD
Midodrine—Feeling abnormal—Epirubicin—prostate cancer	0.00018	0.000358	CcSEcCtD
Midodrine—Somnolence—Doxorubicin—prostate cancer	0.000179	0.000357	CcSEcCtD
Midodrine—Gastrointestinal pain—Epirubicin—prostate cancer	0.000178	0.000355	CcSEcCtD
Midodrine—Dyspepsia—Doxorubicin—prostate cancer	0.000178	0.000354	CcSEcCtD
Midodrine—Rash—Prednisone—prostate cancer	0.000176	0.00035	CcSEcCtD
Midodrine—Dermatitis—Prednisone—prostate cancer	0.000176	0.00035	CcSEcCtD
Midodrine—Headache—Prednisone—prostate cancer	0.000175	0.000348	CcSEcCtD
Midodrine—Gastrointestinal disorder—Doxorubicin—prostate cancer	0.000174	0.000347	CcSEcCtD
Midodrine—Pain—Doxorubicin—prostate cancer	0.000173	0.000344	CcSEcCtD
Midodrine—Abdominal pain—Epirubicin—prostate cancer	0.000172	0.000343	CcSEcCtD
Midodrine—Feeling abnormal—Doxorubicin—prostate cancer	0.000166	0.000331	CcSEcCtD
Midodrine—Nausea—Prednisone—prostate cancer	0.000166	0.00033	CcSEcCtD
Midodrine—Gastrointestinal pain—Doxorubicin—prostate cancer	0.000165	0.000329	CcSEcCtD
Midodrine—Abdominal pain—Doxorubicin—prostate cancer	0.000159	0.000318	CcSEcCtD
Midodrine—Asthenia—Epirubicin—prostate cancer	0.000156	0.000312	CcSEcCtD
Midodrine—Pruritus—Epirubicin—prostate cancer	0.000154	0.000307	CcSEcCtD
Midodrine—Asthenia—Doxorubicin—prostate cancer	0.000145	0.000288	CcSEcCtD
Midodrine—Dizziness—Epirubicin—prostate cancer	0.000144	0.000287	CcSEcCtD
Midodrine—Pruritus—Doxorubicin—prostate cancer	0.000143	0.000284	CcSEcCtD
Midodrine—Rash—Epirubicin—prostate cancer	0.000137	0.000274	CcSEcCtD
Midodrine—Dermatitis—Epirubicin—prostate cancer	0.000137	0.000274	CcSEcCtD
Midodrine—Headache—Epirubicin—prostate cancer	0.000137	0.000272	CcSEcCtD
Midodrine—Dizziness—Doxorubicin—prostate cancer	0.000133	0.000266	CcSEcCtD
Midodrine—Nausea—Epirubicin—prostate cancer	0.00013	0.000258	CcSEcCtD
Midodrine—Rash—Doxorubicin—prostate cancer	0.000127	0.000253	CcSEcCtD
Midodrine—Dermatitis—Doxorubicin—prostate cancer	0.000127	0.000253	CcSEcCtD
Midodrine—Headache—Doxorubicin—prostate cancer	0.000126	0.000252	CcSEcCtD
Midodrine—Nausea—Doxorubicin—prostate cancer	0.00012	0.000239	CcSEcCtD
Midodrine—CYP2D6—Metabolism—GNG5—prostate cancer	2.45e-05	0.000156	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—ADRB2—prostate cancer	2.44e-05	0.000156	CbGpPWpGaD
Midodrine—ADRA1B—GPCR downstream signaling—JAK2—prostate cancer	2.41e-05	0.000154	CbGpPWpGaD
Midodrine—ADRA1A—Signaling by GPCR—PIK3CG—prostate cancer	2.41e-05	0.000154	CbGpPWpGaD
Midodrine—ADRA1D—Signaling by GPCR—CXCL8—prostate cancer	2.41e-05	0.000154	CbGpPWpGaD
Midodrine—ADRA1B—Signaling by GPCR—MAP2K1—prostate cancer	2.4e-05	0.000153	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—ERBB3—prostate cancer	2.39e-05	0.000153	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—FGFR2—prostate cancer	2.39e-05	0.000152	CbGpPWpGaD
Midodrine—ADRA1B—Signaling by GPCR—PIK3CD—prostate cancer	2.39e-05	0.000152	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—VAV3—prostate cancer	2.38e-05	0.000152	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—CASP9—prostate cancer	2.38e-05	0.000152	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—NCOA3—prostate cancer	2.36e-05	0.00015	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—TGFBR2—prostate cancer	2.35e-05	0.00015	CbGpPWpGaD
Midodrine—ADRA1A—GPCR downstream signaling—PIK3CD—prostate cancer	2.33e-05	0.000149	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—ITPR1—prostate cancer	2.31e-05	0.000147	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—PRKCQ—prostate cancer	2.31e-05	0.000147	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—NGFR—prostate cancer	2.31e-05	0.000147	CbGpPWpGaD
Midodrine—ADRA1D—Signaling by GPCR—IL2—prostate cancer	2.3e-05	0.000147	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—TERT—prostate cancer	2.29e-05	0.000146	CbGpPWpGaD
Midodrine—ADRA1B—GPCR downstream signaling—PIK3CB—prostate cancer	2.29e-05	0.000146	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—MAP3K7—prostate cancer	2.28e-05	0.000146	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—HPGDS—prostate cancer	2.25e-05	0.000143	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—CYP2C19—prostate cancer	2.23e-05	0.000142	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—IGF1R—prostate cancer	2.21e-05	0.000141	CbGpPWpGaD
Midodrine—ADRA1B—GPCR downstream signaling—CXCL8—prostate cancer	2.2e-05	0.00014	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—FGF10—prostate cancer	2.19e-05	0.00014	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—HIF1A—prostate cancer	2.19e-05	0.00014	CbGpPWpGaD
Midodrine—ADRA1B—Signaling by GPCR—JAK2—prostate cancer	2.19e-05	0.00014	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—ACHE—prostate cancer	2.18e-05	0.000139	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—GSTT1—prostate cancer	2.18e-05	0.000139	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—ADRB2—prostate cancer	2.17e-05	0.000138	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—CYP2A6—prostate cancer	2.15e-05	0.000137	CbGpPWpGaD
Midodrine—ADRA1A—GPCR downstream signaling—JAK2—prostate cancer	2.14e-05	0.000137	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—LEP—prostate cancer	2.14e-05	0.000136	CbGpPWpGaD
Midodrine—ADRA1A—Signaling by GPCR—MAP2K1—prostate cancer	2.13e-05	0.000136	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—CAV1—prostate cancer	2.12e-05	0.000135	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—LPL—prostate cancer	2.12e-05	0.000135	CbGpPWpGaD
Midodrine—ADRA1A—Signaling by GPCR—PIK3CD—prostate cancer	2.12e-05	0.000135	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—VAV3—prostate cancer	2.12e-05	0.000135	CbGpPWpGaD
Midodrine—ADRA1B—GPCR downstream signaling—IL2—prostate cancer	2.1e-05	0.000134	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—PDGFRB—prostate cancer	2.1e-05	0.000134	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—KDR—prostate cancer	2.1e-05	0.000134	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—AKR1C3—prostate cancer	2.1e-05	0.000134	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—TGFBR2—prostate cancer	2.09e-05	0.000133	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—PRKACB—prostate cancer	2.08e-05	0.000133	CbGpPWpGaD
Midodrine—ADRA1B—Signaling by GPCR—PIK3CB—prostate cancer	2.08e-05	0.000133	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—CYP17A1—prostate cancer	2.06e-05	0.000132	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—ITPR1—prostate cancer	2.05e-05	0.000131	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—ITGB3—prostate cancer	2.05e-05	0.000131	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—ESR1—prostate cancer	2.04e-05	0.00013	CbGpPWpGaD
Midodrine—ADRA1A—GPCR downstream signaling—PIK3CB—prostate cancer	2.03e-05	0.00013	CbGpPWpGaD
Midodrine—ADRA1B—Signaling by GPCR—CXCL8—prostate cancer	2e-05	0.000127	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—BAD—prostate cancer	1.99e-05	0.000127	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—ERBB3—prostate cancer	1.98e-05	0.000127	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—FGFR2—prostate cancer	1.98e-05	0.000126	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—NCOA2—prostate cancer	1.97e-05	0.000125	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—IGF1R—prostate cancer	1.96e-05	0.000125	CbGpPWpGaD
Midodrine—ADRA1A—GPCR downstream signaling—CXCL8—prostate cancer	1.95e-05	0.000125	CbGpPWpGaD
Midodrine—ADRA1A—Signaling by GPCR—JAK2—prostate cancer	1.94e-05	0.000124	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—APC—prostate cancer	1.93e-05	0.000123	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—PIK3CG—prostate cancer	1.93e-05	0.000123	CbGpPWpGaD
Midodrine—ADRA1B—Signaling by GPCR—IL2—prostate cancer	1.91e-05	0.000122	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—EGF—prostate cancer	1.91e-05	0.000122	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—IRS1—prostate cancer	1.91e-05	0.000122	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—TERT—prostate cancer	1.9e-05	0.000121	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—LPL—prostate cancer	1.88e-05	0.00012	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—SLC5A5—prostate cancer	1.88e-05	0.00012	CbGpPWpGaD
Midodrine—ADRA1A—GPCR downstream signaling—IL2—prostate cancer	1.87e-05	0.000119	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—PDGFRB—prostate cancer	1.87e-05	0.000119	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—GSK3B—prostate cancer	1.85e-05	0.000118	CbGpPWpGaD
Midodrine—ADRA1A—Signaling by GPCR—PIK3CB—prostate cancer	1.85e-05	0.000118	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—CYP2E1—prostate cancer	1.83e-05	0.000117	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—INS—prostate cancer	1.83e-05	0.000117	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—HIF1A—prostate cancer	1.82e-05	0.000116	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—ITGB3—prostate cancer	1.82e-05	0.000116	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—NQO1—prostate cancer	1.81e-05	0.000116	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—CREBBP—prostate cancer	1.79e-05	0.000114	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—TH—prostate cancer	1.79e-05	0.000114	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—LEP—prostate cancer	1.78e-05	0.000113	CbGpPWpGaD
Midodrine—ADRA1A—Signaling by GPCR—CXCL8—prostate cancer	1.77e-05	0.000113	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—IGF1—prostate cancer	1.77e-05	0.000113	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—CYP3A4—prostate cancer	1.77e-05	0.000113	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—ERBB3—prostate cancer	1.76e-05	0.000112	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—FGFR2—prostate cancer	1.76e-05	0.000112	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—CAV1—prostate cancer	1.76e-05	0.000112	CbGpPWpGaD
Midodrine—ADRA1D—Signaling by GPCR—EGFR—prostate cancer	1.76e-05	0.000112	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—KDR—prostate cancer	1.74e-05	0.000111	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—CYP1B1—prostate cancer	1.74e-05	0.000111	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—MAP2K1—prostate cancer	1.71e-05	0.000109	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—PIK3CD—prostate cancer	1.7e-05	0.000108	CbGpPWpGaD
Midodrine—ADRA1A—Signaling by GPCR—IL2—prostate cancer	1.7e-05	0.000108	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—ESR1—prostate cancer	1.7e-05	0.000108	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—TERT—prostate cancer	1.69e-05	0.000108	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—GGT1—prostate cancer	1.68e-05	0.000107	CbGpPWpGaD
Midodrine—ADRA1D—GPCR downstream signaling—PIK3CA—prostate cancer	1.68e-05	0.000107	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—SERPINE1—prostate cancer	1.68e-05	0.000107	CbGpPWpGaD
Midodrine—ADRA1D—Signaling by GPCR—KRAS—prostate cancer	1.66e-05	0.000106	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—NCOA1—prostate cancer	1.66e-05	0.000106	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—BAD—prostate cancer	1.65e-05	0.000106	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—CYP19A1—prostate cancer	1.63e-05	0.000104	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—FGF2—prostate cancer	1.63e-05	0.000104	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—HIF1A—prostate cancer	1.62e-05	0.000103	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—NOS3—prostate cancer	1.6e-05	0.000102	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—PIK3CG—prostate cancer	1.6e-05	0.000102	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—APC—prostate cancer	1.6e-05	0.000102	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—IRS1—prostate cancer	1.58e-05	0.000101	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—EGF—prostate cancer	1.58e-05	0.000101	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—LEP—prostate cancer	1.58e-05	0.000101	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—RXRA—prostate cancer	1.58e-05	0.000101	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—CAV1—prostate cancer	1.56e-05	9.97e-05	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—JAK2—prostate cancer	1.56e-05	9.94e-05	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—KDR—prostate cancer	1.55e-05	9.86e-05	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—GSK3B—prostate cancer	1.54e-05	9.81e-05	CbGpPWpGaD
Midodrine—ADRA1D—Signaling by GPCR—PIK3CA—prostate cancer	1.53e-05	9.74e-05	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—MDM2—prostate cancer	1.52e-05	9.7e-05	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—COMT—prostate cancer	1.52e-05	9.68e-05	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—INS—prostate cancer	1.52e-05	9.68e-05	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—GSTP1—prostate cancer	1.51e-05	9.64e-05	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—ESR1—prostate cancer	1.51e-05	9.61e-05	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—ERBB2—prostate cancer	1.5e-05	9.57e-05	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—ITPR1—prostate cancer	1.49e-05	9.48e-05	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—CREBBP—prostate cancer	1.49e-05	9.48e-05	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—PIK3CB—prostate cancer	1.48e-05	9.44e-05	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—BAD—prostate cancer	1.47e-05	9.38e-05	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—IGF1—prostate cancer	1.47e-05	9.36e-05	CbGpPWpGaD
Midodrine—ADRA1B—Signaling by GPCR—EGFR—prostate cancer	1.46e-05	9.32e-05	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—APC—prostate cancer	1.42e-05	9.08e-05	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—PIK3CG—prostate cancer	1.42e-05	9.08e-05	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—CXCL8—prostate cancer	1.42e-05	9.07e-05	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—MAP2K1—prostate cancer	1.42e-05	9.05e-05	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—PIK3CD—prostate cancer	1.41e-05	8.99e-05	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—EGF—prostate cancer	1.41e-05	8.98e-05	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—IRS1—prostate cancer	1.41e-05	8.98e-05	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—TYMS—prostate cancer	1.4e-05	8.96e-05	CbGpPWpGaD
Midodrine—ADRA1B—GPCR downstream signaling—PIK3CA—prostate cancer	1.4e-05	8.9e-05	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—SERPINE1—prostate cancer	1.39e-05	8.89e-05	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—CDKN1B—prostate cancer	1.39e-05	8.86e-05	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—GSTM1—prostate cancer	1.39e-05	8.86e-05	CbGpPWpGaD
Midodrine—ADRA1B—Signaling by GPCR—KRAS—prostate cancer	1.38e-05	8.8e-05	CbGpPWpGaD
Midodrine—ADRA1D—GPCR downstream signaling—AKT1—prostate cancer	1.37e-05	8.76e-05	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—GSK3B—prostate cancer	1.37e-05	8.71e-05	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—LPL—prostate cancer	1.36e-05	8.69e-05	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—CASP3—prostate cancer	1.36e-05	8.68e-05	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—IL2—prostate cancer	1.36e-05	8.67e-05	CbGpPWpGaD
Midodrine—ADRA1D—Signaling by GPCR—IL6—prostate cancer	1.35e-05	8.63e-05	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—FGF2—prostate cancer	1.35e-05	8.61e-05	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—INS—prostate cancer	1.35e-05	8.6e-05	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—NOS3—prostate cancer	1.33e-05	8.49e-05	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—CCND1—prostate cancer	1.32e-05	8.45e-05	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—CREBBP—prostate cancer	1.32e-05	8.42e-05	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—CYP1A1—prostate cancer	1.32e-05	8.4e-05	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—CTNNB1—prostate cancer	1.31e-05	8.37e-05	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—ERCC2—prostate cancer	1.31e-05	8.33e-05	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—IGF1—prostate cancer	1.3e-05	8.32e-05	CbGpPWpGaD
Midodrine—ADRA1A—Signaling by GPCR—EGFR—prostate cancer	1.3e-05	8.27e-05	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—JAK2—prostate cancer	1.29e-05	8.25e-05	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—MMP9—prostate cancer	1.29e-05	8.2e-05	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—CDKN1A—prostate cancer	1.28e-05	8.18e-05	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—PTEN—prostate cancer	1.28e-05	8.16e-05	CbGpPWpGaD
Midodrine—ADRA1B—Signaling by GPCR—PIK3CA—prostate cancer	1.27e-05	8.08e-05	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—MDM2—prostate cancer	1.26e-05	8.05e-05	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—MAP2K1—prostate cancer	1.26e-05	8.04e-05	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—PIK3CD—prostate cancer	1.25e-05	7.98e-05	CbGpPWpGaD
Midodrine—ADRA1D—Signaling by GPCR—AKT1—prostate cancer	1.25e-05	7.96e-05	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—ERBB2—prostate cancer	1.24e-05	7.94e-05	CbGpPWpGaD
Midodrine—ADRA1A—GPCR downstream signaling—PIK3CA—prostate cancer	1.24e-05	7.91e-05	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—SERPINE1—prostate cancer	1.24e-05	7.9e-05	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—PIK3CB—prostate cancer	1.23e-05	7.83e-05	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—MTHFR—prostate cancer	1.23e-05	7.83e-05	CbGpPWpGaD
Midodrine—ADRA1A—Signaling by GPCR—KRAS—prostate cancer	1.23e-05	7.82e-05	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—EP300—prostate cancer	1.22e-05	7.78e-05	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—PPARA—prostate cancer	1.2e-05	7.68e-05	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—FGF2—prostate cancer	1.2e-05	7.64e-05	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—SRC—prostate cancer	1.19e-05	7.56e-05	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—NOS3—prostate cancer	1.18e-05	7.54e-05	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—CXCL8—prostate cancer	1.18e-05	7.53e-05	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—VEGFA—prostate cancer	1.15e-05	7.37e-05	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—CDKN1B—prostate cancer	1.15e-05	7.35e-05	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—JAK2—prostate cancer	1.15e-05	7.33e-05	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—STAT3—prostate cancer	1.14e-05	7.29e-05	CbGpPWpGaD
Midodrine—ADRA1B—GPCR downstream signaling—AKT1—prostate cancer	1.14e-05	7.27e-05	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—CAV1—prostate cancer	1.13e-05	7.22e-05	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—CASP3—prostate cancer	1.13e-05	7.21e-05	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—IL2—prostate cancer	1.13e-05	7.2e-05	CbGpPWpGaD
Midodrine—ADRA1A—Signaling by GPCR—PIK3CA—prostate cancer	1.13e-05	7.18e-05	CbGpPWpGaD
Midodrine—ADRA1B—Signaling by GPCR—IL6—prostate cancer	1.12e-05	7.16e-05	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—MDM2—prostate cancer	1.12e-05	7.15e-05	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—ERBB2—prostate cancer	1.11e-05	7.05e-05	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—CCND1—prostate cancer	1.1e-05	7.01e-05	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—PIK3CB—prostate cancer	1.09e-05	6.96e-05	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—CTNNB1—prostate cancer	1.09e-05	6.95e-05	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—MMP9—prostate cancer	1.07e-05	6.81e-05	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—CDKN1A—prostate cancer	1.06e-05	6.79e-05	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—MYC—prostate cancer	1.06e-05	6.78e-05	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—PTEN—prostate cancer	1.06e-05	6.77e-05	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—TGFB1—prostate cancer	1.06e-05	6.76e-05	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—CXCL8—prostate cancer	1.05e-05	6.69e-05	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—EGFR—prostate cancer	1.04e-05	6.63e-05	CbGpPWpGaD
Midodrine—ADRA1B—Signaling by GPCR—AKT1—prostate cancer	1.04e-05	6.6e-05	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—PIK3CG—prostate cancer	1.03e-05	6.58e-05	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—CDKN1B—prostate cancer	1.02e-05	6.53e-05	CbGpPWpGaD
Midodrine—ADRA1A—GPCR downstream signaling—AKT1—prostate cancer	1.01e-05	6.46e-05	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—EP300—prostate cancer	1.01e-05	6.46e-05	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—CASP3—prostate cancer	1e-05	6.4e-05	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—IL2—prostate cancer	1e-05	6.39e-05	CbGpPWpGaD
Midodrine—ADRA1A—Signaling by GPCR—IL6—prostate cancer	9.97e-06	6.36e-05	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—SRC—prostate cancer	9.84e-06	6.28e-05	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—KRAS—prostate cancer	9.82e-06	6.26e-05	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—CCND1—prostate cancer	9.77e-06	6.23e-05	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—INS—prostate cancer	9.76e-06	6.22e-05	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—CTNNB1—prostate cancer	9.67e-06	6.17e-05	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—VEGFA—prostate cancer	9.59e-06	6.11e-05	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—CREBBP—prostate cancer	9.56e-06	6.1e-05	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—STAT3—prostate cancer	9.49e-06	6.05e-05	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—MMP9—prostate cancer	9.48e-06	6.05e-05	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—CDKN1A—prostate cancer	9.45e-06	6.03e-05	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—PTEN—prostate cancer	9.43e-06	6.01e-05	CbGpPWpGaD
Midodrine—ADRA1A—Signaling by GPCR—AKT1—prostate cancer	9.2e-06	5.87e-05	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—PIK3CD—prostate cancer	9.06e-06	5.78e-05	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—PIK3CA—prostate cancer	9.02e-06	5.75e-05	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—EP300—prostate cancer	8.99e-06	5.73e-05	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—MYC—prostate cancer	8.82e-06	5.63e-05	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—TGFB1—prostate cancer	8.8e-06	5.61e-05	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—SRC—prostate cancer	8.74e-06	5.58e-05	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—TP53—prostate cancer	8.73e-06	5.57e-05	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—EGFR—prostate cancer	8.63e-06	5.5e-05	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—NOS3—prostate cancer	8.56e-06	5.46e-05	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—VEGFA—prostate cancer	8.51e-06	5.43e-05	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—STAT3—prostate cancer	8.43e-06	5.38e-05	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—KRAS—prostate cancer	8.15e-06	5.2e-05	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—IL6—prostate cancer	7.99e-06	5.1e-05	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—PIK3CB—prostate cancer	7.9e-06	5.04e-05	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—MYC—prostate cancer	7.83e-06	5e-05	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—PTGS2—prostate cancer	7.83e-06	4.99e-05	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—TGFB1—prostate cancer	7.81e-06	4.99e-05	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—EGFR—prostate cancer	7.66e-06	4.89e-05	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—PIK3CA—prostate cancer	7.49e-06	4.78e-05	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—AKT1—prostate cancer	7.37e-06	4.7e-05	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—TP53—prostate cancer	7.24e-06	4.62e-05	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—KRAS—prostate cancer	7.24e-06	4.62e-05	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—PTEN—prostate cancer	6.83e-06	4.35e-05	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—PIK3CA—prostate cancer	6.65e-06	4.24e-05	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—IL6—prostate cancer	6.63e-06	4.23e-05	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—EP300—prostate cancer	6.51e-06	4.15e-05	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—TP53—prostate cancer	6.43e-06	4.1e-05	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—AKT1—prostate cancer	6.12e-06	3.9e-05	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—IL6—prostate cancer	5.89e-06	3.76e-05	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—AKT1—prostate cancer	5.43e-06	3.47e-05	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—PIK3CA—prostate cancer	4.82e-06	3.07e-05	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—AKT1—prostate cancer	3.93e-06	2.51e-05	CbGpPWpGaD
